Fat loss.

That is the shallow read.
The more useful conversation is signal layering.

Retatrutide and Tesamorelin do not sit in the same research category.
That is the point.

Retatrutide is commonly discussed around multi-receptor metabolic signaling:

GLP-1.
GIP.
Glucagon.

Tesamorelin is commonly discussed around GHRH signaling and GH-axis research models.

Different lanes.
Different mechanisms.
Different research logic.

This is not simply:
“What burns fat?”

That is beginner thinking.

The better question is:
“What signals are being studied — and how do they change the metabolic environment?”

Retatrutide belongs closer to:

Appetite-regulation models.
Fuel-handling research.
Glucose-related pathways.
Energy-expenditure models.
Advanced metabolic signaling.

Tesamorelin belongs closer to:

GH-axis signaling.
Body-composition research.
Tissue-partitioning models.
Metabolic-environment research.

That is what makes the stack conversation more interesting.
Not because stacking compounds automatically makes the model better.
Not because it is magic.
Because researchers are not only looking at scale weight.

They are looking at the environment underneath body composition:

Appetite.
Fuel use.
Metabolic signaling.
GH-axis activity.
Tissue partitioning.
Energy regulation.

That is a deeper conversation than “weight loss.”

Inside the Discord, we break this down properly.

Not surface-level stack chasing.
Not “best peptide for fat loss.”
Not random compound collecting.

We look at the category, the mechanism, and the model before the hype takes over.

— The Biohacker Network